Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump’s 100% tariff threat looms over patented drugs
​Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump’s 100% tariff threat looms over patented drugs by Soban News (international And National News)